|
|
 |
|
Viewing report
|
|
|
|
Pipeline Insight: Disease Modification In Rheumatoid Arthritis - Competition For The Anti-TNF Failure Patient Population Increases
Datamonitor, April 2007, Pages: 222
The treatment of Rheumatoid Arthritis (RA) has been rapidly evolving over the last decade. The success of the next wave of novel RA therapies depends on their ability to address the key issue of cost effectiveness, as the patient population for anti-TNFs is reaching a maximum and competition moves to anti-TNF failure patients.
Scope of this title:
Detailed pipeline analysis for key products in a specific rheumatoid arthritis indication, plus drug sales forecasts to 2016 Overview of patient potential, segmentation by indication and unmet needs in rheumatoid arthritis across the seven major markets Benchmarking of key clinical and company attractiveness of the late-phase pipeline products Comprehensive and up-to-date clinical trial information
Highlights of this title:
The anti-TNF failure segment will be an area of increased competition over the next five years, as new products avoid direct confrontation with the established anti-TNFs. This population will increase as more patients use biologics and cycle through the anti-TNFs, but there are a finite number of eligible patients, especially if prices remain high. The race is on between the Roche/Genentech/Biogen Idec and the Genmab/GSK partnerships to launch a CD20-inhibiting monoclonal antibody to follow, and build upon, the success shown by Rituxan/MabThera (rituximab) in the RA indication. At present Roche with ocrelizumab have a slight, but uncertain, advantage. The majority (58%) of projects in human clinical trials are in Phase II development showing the positive growth potential in the RA disease area. However, a large proportion are small molecule, orally available products, which have in the past shown a high attrition rate in Phase II.
Reasons to order your copy:
Understand why pricing restraint is necessary for the continued exponential uptake and commercial growth of the biologic DMARDs Quantify the future size and potential of the market for novel treatments in the rheumatoid arthritis indication Use analysis of the common molecular targets under investigation to find gaps in the market for your product
Customers who bought this item also bought
Pipeline Insight: Disease Modification in Rheumatoid Arthritis - New drug targets compete in crowded market
The Rheumatoid Arthritis Market - Competitive Landscape and Clinical Stage Analysis
Rheumatoid Arthritis Drug Discoveries: What The Future Holds
Therapeutic Clinical Intelligence - Rheumatoid Arthritis - 2009 Edition
Trial TRAX - Rheumatoid Arthritis - Clinical Trial Monitoring Brief
Rheumatoid Arthritis: Market Trends and R&D Insights
Disease Modification In Rheumatoid Arthritis - Pipeline Uptake Inhibited By Anti-Tnfs
Pipeline Insight: Rheumatoid Arthritis and Osteoarthritis - Striving for innovation among me-toos
Improved Diagnostic and Prognostic Tools for Rheumatoid Arthritis: Unmet Needs in a Changing Market
Commercial and Pipeline Perspectives: Rheumatoid Arthritis - Novel Biologics Drive Innovation in the Global RA Market
Rheumatoid Arthritis Therapy Area Pipeline Report
Autoimmune And Inflammation Rheumatoid Arthritis
|
|
|
|
